PLAQUE PSORIASIS

This study tests a new oral medication, JNJ-77242113, for people with moderate to severe plaque psoriasis. About 731 adults will receive either the new drug, a placebo (inactive pill), or an active comparator (another approved drug). The main goal is to see how well the new drug …

This study looks at the long-term safety and effectiveness of the drug ESK-001 in people with plaque psoriasis who have already completed an earlier ESK-001 study. About 165 adults will take the drug for an extended period to track side effects and see how well it controls psoria…

This study tests an oral medication called JNJ-77242113 for people with moderate to severe plaque psoriasis. About 684 adults will receive either the drug or a placebo to see if it can clear or greatly improve their skin. The trial also includes a withdrawal phase to see how long…

This study tests an experimental drug, JNJ-77242113, to see how well it clears skin plaques in people with moderate to severe psoriasis. About 752 adults will receive either the new drug, a placebo (inactive pill), or an existing treatment (ustekinumab). The main goal is to measu…

This study tests an experimental drug called ORKA-001 in 80 adults with moderate-to-severe plaque psoriasis. Participants receive either the drug or a placebo to see if it can clear skin lesions. The main goal is to measure complete skin clearance at 16 weeks.

This study tests a new medicine called CT-P55 against the approved drug Cosentyx in 153 adults with moderate to severe plaque psoriasis. The goal is to see if CT-P55 works as well and is as safe. Participants must have had psoriasis for at least 6 months and cannot have used cert…

This study tests whether the drug apremilast can safely and effectively treat moderate to severe plaque psoriasis in Japanese children and teens aged 6 to 17. Participants take the medication and are monitored for skin clearing and side effects. The goal is to control the disease…

This study tests a new oral medication, JNJ-77242113, for adults with moderate to severe plaque psoriasis. It compares the drug to a placebo and another active treatment (deucravacitinib) to see how well it clears skin lesions. About 774 participants will take the pill daily for …

This study follows 550 adults in Germany with moderate-to-severe plaque psoriasis who are starting deucravacitinib, a daily pill. Researchers will check how well the drug clears skin and improves quality of life over 5 years in routine medical practice. The goal is to see if resu…

This study tests an oral medication called JNJ-77242113 for people with plaque psoriasis affecting special areas like the scalp, genitals, or palms and soles. About 311 adults who need systemic treatment will receive either the drug or a placebo for 16 weeks. The main goal is to …

This study looks at how well the drug deucravacitinib works for adults with moderate plaque psoriasis in everyday medical practice in China. Researchers will track 153 participants to see if their skin clears up and how much it improves. The goal is to understand the drug's real-…

This study tests a new medication called picankibart in about 308 adults with plaque psoriasis who did not get enough relief from common biologic drugs (IL-17 inhibitors). Participants will switch to picankibart or an active control to see if it better clears skin symptoms. The t…

This study looks at the long-term safety and effectiveness of the drug ESK-001 in adults with moderate to severe plaque psoriasis. Participants must have completed a prior ESK-001 study. They will take ESK-001 twice daily for 24 weeks, then some may switch to a placebo to see if …

This study checks the long-term safety and side effects of the drug TAK-279 in adults with moderate-to-severe plaque psoriasis. About 1,950 participants will take the drug for up to 208 weeks, with regular clinic visits. The goal is to see how well people tolerate the treatment o…

This study looks at how the drug guselkumab affects immune cells in people with two types of psoriasis: plaque and guttate. Researchers will measure changes in skin cells that produce a protein called IL-17. The goal is to better understand how the drug works in these conditions.…

This study tests a cream called tapinarof in 58 children aged 2 to 17 with plaque psoriasis. The goal is to see if the cream is safe and how it affects skin irritation. Children apply the cream daily, and doctors monitor for side effects and skin reactions.

This study looks at how safe the drug apremilast is for children and teens aged 6 to 17 with mild to moderate plaque psoriasis. About 51 participants will take the drug and be monitored for side effects, growth, and development. The goal is to make sure the treatment is safe for …

This study tests whether a daily pill called IRX4204 can safely improve skin symptoms in adults with mild to moderate plaque psoriasis. About 20 participants will take the drug or a placebo for 28 days and have weekly checkups. The goal is to see if the drug clears or nearly clea…